Feb 16 Numerous small biotechnology companies have been all but shut out of the capital markets, leaving many with no choice but to consider a sale to larger peers. The Nasdaq Biotech Index is down nearly 30 percent since September, when Democratic presidential candidate Hillary Clinton criticized drug companies' "price gouging" on Twitter and sparked concerns about a government crackdown on rising drug costs.